Home > Compound List > Compound details
362-07-2 molecular structure
click picture or here to close

(1S,10R,11S,14S,15S)-4-methoxy-15-methyltetracyclo[8.7.0.02,7.011,15]heptadeca-2,4,6-triene-5,14-diol

ChemBase ID: 72585
Molecular Formular: C19H26O3
Molecular Mass: 302.40794
Monoisotopic Mass: 302.18819469
SMILES and InChIs

SMILES:
c1(c(cc2c(c1)[C@@H]1[C@@H](CC2)[C@H]2[C@](CC1)([C@H](CC2)O)C)O)OC
Canonical SMILES:
COc1cc2c(cc1O)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2O)C
InChI:
InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1
InChIKey:
CQOQDQWUFQDJMK-SSTWWWIQSA-N

Cite this record

CBID:72585 http://www.chembase.cn/molecule-72585.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
(1S,10R,11S,14S,15S)-4-methoxy-15-methyltetracyclo[8.7.0.02,7.011,15]heptadeca-2,4,6-triene-5,14-diol
(1S,10R,11S,14S,15S)-4-methoxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2,4,6-triene-5,14-diol
(1S,10R,11S,14S,15S)-4-methoxy-15-methyltetracyclo[8.7.0.02,7.011,15]heptadeca-2(7),3,5-triene-5,14-diol
IUPAC Traditional name
2-methoxyestradiol
Synonyms
1,3,5(10)-Estratriene-2,3,17β-triol 2-methyl ether
2-Methoxy-estra-1,3,5(10)-triene-3,17β-diol
1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether
2,3,17β-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether
2-Hydroxyestradiol 2-methyl ether
3,17β-Dihydroxy-2-methoxy-1,3,5(10)-estratriene
2-Methoxyestradiol
2-ME2
2-Methoxyestradiol
(17β)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol
2-Methoxyestra-1,3,5(10)-triene-3,17β-diol
2-Methoxyestradiol
NSC 659853
Panzem
2-Methoxy 17β-Estradiol
CAS Number
362-07-2
MDL Number
MFCD00010489
Beilstein Number
3147966
PubChem SID
24278561
162037510
PubChem CID
66414

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID
PubChem 66414 external link

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem
Acid pKa 10.290903  H Acceptors
H Donor LogD (pH = 5.5) 3.587823 
LogD (pH = 7.4) 3.5872755  Log P 3.58783 
Molar Refractivity 86.3679 cm3 Polarizability 33.824192 Å3
Polar Surface Area 49.69 Å2 Rotatable Bonds
Lipinski's Rule of Five true 

PROPERTIES

PROPERTIES

Physical Property Safety Information Pharmacology Properties Product Information Bioassay(PubChem)
Solubility
Chloroform expand Show data source
DMSO: soluble10 mg/mL expand Show data source
ethanol: soluble10 mg/mL expand Show data source
H2O: insoluble expand Show data source
Methanol expand Show data source
Apperance
Off-White Solid expand Show data source
white to faint yellow powder expand Show data source
Melting Point
188-190°C expand Show data source
Storage Condition
-20°C expand Show data source
-20°C Freezer expand Show data source
RTECS
KG7537500 expand Show data source
European Hazard Symbols
Nature polluting Nature polluting (N) expand Show data source
Toxic Toxic (T) expand Show data source
UN Number
3077 expand Show data source
MSDS Link
Download expand Show data source
Download expand Show data source
German water hazard class
3 expand Show data source
Hazard Class
9 expand Show data source
Packing Group
3 expand Show data source
Risk Statements
45-46-60-61-23/24/25-36/37/38-48 expand Show data source
45-46-60-61-23/24/25-36/37/38-48-51/53 expand Show data source
Safety Statements
53-22-26-36/37/39-45 expand Show data source
53-22-26-36/37/39-45-61 expand Show data source
GHS Pictograms
GHS06 expand Show data source
GHS08 expand Show data source
GHS09 expand Show data source
GHS Signal Word
Danger expand Show data source
GHS Hazard statements
H301 + H311 + H331-H315-H319-H335-H350-H360-H372-H410 expand Show data source
H301-H311-H315-H319-H331-H335-H350-H360-H372 expand Show data source
GHS Precautionary statements
P201-P261-P273-P280-P301 + P310-P305 + P351 + P338 expand Show data source
P201-P261-P280-P301 + P310-P305 + P351 + P338-P311 expand Show data source
Personal Protective Equipment
Eyeshields, Faceshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges expand Show data source
RID/ADR
UN 3077 9/PG 3 expand Show data source
Storage Temperature
-20°C expand Show data source
Target
HIF expand Show data source
Gene Information
human ... ESR1(2099), ESR2(2100) expand Show data source
Purity
≥98.0% (HPLC) expand Show data source
Grade
purum expand Show data source
Salt Data
Free Base expand Show data source
Certificate of Analysis
Download expand Show data source
Empirical Formula (Hill Notation)
C19H26O3 expand Show data source

DETAILS

DETAILS

Selleck Chemicals Selleck Chemicals Sigma Aldrich Sigma Aldrich TRC TRC
Selleck Chemicals - S1233 external link
Research Area
Description Pulmonary hypertension
Biological Activity
Description 2-Methoxyestradiol is an endogenous estrogen metabolite and naturally occurring mammalian tubulin polymerization inhibitor.
Targets
IC50
In Vitro 2-Methoxyestradiol exhibits the inhibitory activity of cellular proliferation in a breast carcinoma cell line MDA-MB-435 and an ovarian carcinoma cell line SK-OV-3 with IC50 of 1.38 μM and 1.79 μM, respectively. Furthermore, 2-Methoxyestradiol also inhibits cellular microtubule depolymerization in rat aortic smooth muscle A-10 cells with EC50 of 7.5 μM. [1] 2-Methoxyestradiol inhibits proliferation of MCF-7 and BM cells with IC50 of 52 μM and 8 μM. [2] In MDA-MB-231 cells, 2-Methoxyestradiol inhibits HIF-1-mediated transcriptional activation of target genes without affecting the transcription of HIF-1α itself. [3] A recent study shows that 2-Methoxyestradiol (0.5 μM), blocks TGF-β3-induced expression of collagen (Col) type I(αI), Col III(αI), plasminogen activator inhibitor (PAI) 1, connective tissue growth factor (CTGF), and α-smooth muscle actin (α-SMA). Moreover, 2-Methoxyestradiol ameliorates TGF-β3-induced Smad2/3 phosphorylation and nuclear translocation, and inhibits TGF-β3-induced activation of the PI3K/Akt/mTOR pathway. [4]
In Vivo In a 9L rat glioma (9L-V6R) rat model, 2-Methoxyestradiol significantly decreases HIF-1 activity and inhibits the tumor growth in a dose-dependent manner by 4-fold reduction for 60 mg/kg/day, and 23-fold reduction for 600 mg/kg/day, respectively. [5]
Clinical Trials 2-Methoxyestradiol is currently in Phase II clinical trials in patients with plateau Phase or relapsed multiple myeloma. Combination treatment of 2-Methoxyestradiol and Bevacizumab is currently in Phase II clinical trials in patients with locally advanced or metastatic carcinoid tumors.
Features
Combination Therapy
Description While the combination of 2-Methoxyestradiol and 4-Hydroxytamoxifen leads to the more potent inhibition of proliferation of MCF-7 and BM cells with IC50 of 6 μM and 4 μM, respectively. [2] In a AsPC-1 mouse model, the combination therapy of 2-Methoxyestradiol and gemcitabine leads to a significant reduction of average tumor volume by 83% compared to the non-treated group, while 2-Methoxyestradiol (2 mg) alone leads to a growth inhibition of 63% with no evident toxicity. [6]
Protocol
Kinase Assay [1]
Microtubule depolymerizing activity The effects of 2-Methoxyestradiol on cellular microtubule depolymerization are determined by indirect immunofluorescence techniques in rat aortic smooth muscle A-10 cells. Microtubules are visualized using a β-tubulin antibody. Three viewers determines the percent microtubule loss for each treatment concentration. The data are averaged and plotted as percent microtubule loss versus drug concentration and the EC50s for microtubule depolymerization calculated from the log dose–response curves.
Cell Assay [1]
Cell Lines MDA-MB-435 and SK-OV-3
Concentrations 0-20 μM
Incubation Time 48 hours
Methods The sulforhodamine B (SRB) assay is used to evaluate the antiproliferative activity of 2-Methoxyestradiol in the MDA-MB-435 and SK-OV-3 cell lines. Cells a plated into 96-well plates and allowed to grow and attach for 24 hours followed by addition of 2-Methoxyestradiol or vehicle controls. The cells are incubated with drugs for 48 hours and then the cellular protein is fixed, stained, and concentration determined by absorbance at 560 nm. Log dose–response curves are constructed for each experiment and the IC50 for inhibition of proliferation determined.
Animal Study [5]
Animal Models 9L-V6R cells are injected into the brains of Fischer 344 rats
Formulation 2-Methoxyestradiol is dissolved in DMSO.
Doses ≤600 mg/kg
Administration Administered via i.p.
References
[1] Rao PN, et al. Steroids. 2002, 67(13-14), 1079-1089.
[2] Seeger H, et al. J Steroid Biochem Mol Biol. 2003, 84(2-3), 255-257.
[3] Mabjeesh NJ, et al. Cancer Cell. 2003, 3(4), 363-375.
[4] Salama SA, et al. Fertil Steril. 2012.
[5] Kang SH, et al. Cancer Res. 2006, 66(24),11991-11997.
[6] Fotopoulou C, et al. Anticancer Res. 2010, 30(11), 4619-4624.
Sigma Aldrich - M6383 external link
Biochem/physiol Actions
2-Methoxyestradiol (2-ME) is a potent inhibitor of endothelial cell proliferation and angiogenesis. A major estradiol metabolite, it has little affinity for classical estrogen receptors.
Other Notes
Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. M6383.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.
Toronto Research Chemicals - M262625 external link
2-Methoxy 17β-Estradiol is a natural metabolite of 17β-Estradiol which is devoid of estrogenic activity. Inhibits cell proliferation and angiogenesis. 2-Methoxy 17β-Estradiol binds to the colchicine binding site of tubulin, and has been suggested to func

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle